Circulating tumor DNA exposure in peripheral blood using a novel process: A feasibility study.

Withdrawn

• Conditions: Cancer; carcinoma; 10027655

• Registration Number: NL-OMON46123
• Lead Sponsor: Quantgene inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 500

Inclusion Criteria

Subjects of both cohorts must:
- Be of age * 18 years
- Provide written consent for study participation;Subjects of cohort 1 must:
- Have a diagnosis of one of the following malignancies in clinical stage 0 to IV: non-small lung cancer, gastric cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colorectal cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, adrenocortical cancer, breast cancer, ovarian cancer, cervical cancer, adrenocortical cancer, melanoma and leukemia.;Subjects of cohort 2 must:
- Are planned for surgery in the foreseeable future, to guarantee a blood sample.

Exclusion Criteria

Subjects of cohort 1 must not:
- Have been treated for above diagnosed malignancy ;Subjects of cohort 2 must not
- Have been diagnosed or treated for a malignancy previously

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study endpoint is sensitivity and specificity of the novel ctDNA<br /><br>detection process. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>